Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 28, 2026, 8:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hydroxychloroquine Clear all
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)

NCT04318444
View directory record Official record
Conditions
COVID-19, Corona Virus Infection
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Jun 28, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis

NCT01132118
View directory record Official record
Conditions
Rheumatoid Arthritis, Insulin Resistance
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Jun 28, 2026, 8:15 AM EDT
Completed Phase 1 Interventional

Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00568880
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bortezomib, hydroxychloroquine
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Jun 28, 2026, 8:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas

NCT01128296
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Hydroxychloroquine, Gemcitabine
Drug
Lead sponsor
Amer Zureikat
Other
Eligibility
19 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Jun 28, 2026, 8:15 AM EDT
Terminated Phase 3 Interventional

A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients

NCT04345692
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years to 95 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 28, 2026, 8:15 AM EDT
Completed Phase 1 Interventional

Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01689987
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Cyclophosphamide, Dexamethasone, Hydroxychloroquine, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Jun 28, 2026, 8:15 AM EDT
Recruiting Phase 1 Interventional

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

NCT04678648
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
Interventions
RSC-1255 Dose Escalation, RSC-1255 Dose Expansion
Drug
Lead sponsor
RasCal Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 28, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers

NCT04345653
View directory record Official record
Conditions
Covid19
Interventions
Hydroxychloroquine Sulfate (HCQ)
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 99 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Jun 28, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts

NCT04652648
View directory record Official record
Conditions
Covid19, Hydroxychloroquine, Coronavirus Infection, Transmission, Prophylaxis
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Bryn Mawr Hospital
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Bryn Mawr, Pennsylvania • Paoli, Pennsylvania • Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Jun 28, 2026, 8:15 AM EDT
Terminated Phase 2 Interventional Results available

Hydroxychloroquine in Untreated B-CLL Patients

NCT00771056
View directory record Official record
Conditions
B-Cell Chronic Lymphocytic Leukemia
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2016 · Synced Jun 28, 2026, 8:15 AM EDT
Terminated Phase 2 Interventional Results available

Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus

NCT02303405
View directory record Official record
Conditions
Diabetes Mellitus Type 2 With Hyperglycemia
Interventions
Hydroxychloroquine, Pioglitazone
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Jun 28, 2026, 8:15 AM EDT
Completed Phase 1Phase 2 Interventional

To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

NCT04593758
View directory record Official record
Conditions
Sarcoma, Clear Cell
Interventions
CPI-613 + Hydroxychloroquine
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
2 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Duarte, California • Kansas City, Kansas • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Jun 28, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Results available

Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine

NCT01978184
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine, abraxane, hydroxychloroquine
Drug
Lead sponsor
Nathan Bahary, MD
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Jun 28, 2026, 8:15 AM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19

NCT04358068
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
Hydroxychloroquine (HCQ), Azithromycin (Azithro), Placebo for Hydroxychloroquine, Placebo for Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Jun 28, 2026, 8:15 AM EDT
Not listed Phase 2 Interventional

Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer

NCT01494155
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Capecitabine, Hydroxychloroquine, Proton or Photon Radiation Therapy
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jun 28, 2026, 8:15 AM EDT
Completed Early Phase 1 Interventional

Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

NCT00962845
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Jun 28, 2026, 8:15 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer

NCT01506973
View directory record Official record
Conditions
Advanced Adenocarcinoma, Metastatic Adenocarcinoma
Interventions
Hydroxychloroquine (HCQ), Gemcitabine, Abraxane
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Jun 28, 2026, 8:15 AM EDT
Completed Phase 1 Interventional

Hydroxychloroquine in Cystic Fibrosis

NCT00311883
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
hydroxychloroquine
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
16 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Jun 28, 2026, 8:15 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)

NCT04329923
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine Sulfate 400 mg twice a day, Hydroxychloroquine Sulfate 600 mg twice a day, Hydroxychloroquine Sulfate 600 mg once a day, Placebo oral tablet
Drug
Lead sponsor
Ravi Amaravadi, MD
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Jun 28, 2026, 8:15 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma

NCT04464759
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Hydroxychloroquine, Ipilimumab
Drug
Lead sponsor
Ravi Amaravadi, MD
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jun 28, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Results available

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

NCT04524702
View directory record Official record
Conditions
Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Gemcitabine, Hydroxychloroquine, Nab-paclitaxel, Paricalcitol
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jun 28, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection

NCT04335084
View directory record Official record
Conditions
COVID-19, Coronavirus Infection, Sars-CoV2, Corona Virus Infection, COVID, Coronavirus, Coronavirus-19, Coronavirus 19
Interventions
Hydroxychloroquine, Vitamin C, Vitamin D, Zinc
Drug · Dietary Supplement
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jun 28, 2026, 8:15 AM EDT
Terminated Phase 1 Interventional

Hydroxychloroquine in Outpatient Adults With COVID-19

NCT04333654
View directory record Official record
Conditions
Coronavirus Infection
Interventions
Hydroxychloroquine SAR321068, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Jun 28, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT

NCT03283566
View directory record Official record
Conditions
Chronic Pancreatitis, Insulin Dependent Diabetes
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Jun 28, 2026, 8:15 AM EDT